C26 - Intérêt de la scintigraphie au fdg 18 dans la détection des neurofibrosarcomes au cours de la neurofibromatose de type 1
P. Combemale(Centre Léon Bérard), Francesco Giammarile(International Atomic Energy Agency), M Dupin, Thomas Mognetti(Centre de Recherche en Cancérologie de Lyon), A. Drouet(Hôpital d'instruction des Armées Desgenettes), Isabelle Morelec(Hospices Civils de Lyon), S. Pinson(Hôpital Edouard Herriot)
Cited by 0
Related Papers
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
|Neuroendocrinology|2017|495
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
|Journal of the European Academy of Dermatology and Venereology|2017|192